Header Logo

Connection

Mark Pollack to Pseudomonas aeruginosa

Back to Details
This is a "connection" page, showing publications Mark Pollack has written about Pseudomonas aeruginosa.
Mark Pollack
Connection Strength
1.278
Pseudomonas aeruginosa
  1. Antibacterial properties of Pseudomonas aeruginosa immunotype 1 lipopolysaccharide-specific monoclonal antibody (MAb) in a murine thigh infection model: combined effects of MAb and ceftazidime. Microbiol Immunol. 2000; 44(8):629-35.
    View in: PubMed
    Score: 0.165
  2. Functional properties of isotype-switched immunoglobulin M (IgM) and IgG monoclonal antibodies to Pseudomonas aeruginosa lipopolysaccharide. Infect Immun. 1995 Nov; 63(11):4481-8.
    View in: PubMed
    Score: 0.124
  3. Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06. Infect Immun. 1994 Apr; 62(4):1137-43.
    View in: PubMed
    Score: 0.111
  4. In vitro and in vivo functional activities of monoclonal antibodies reactive with Pseudomonas aeruginosa serogroup 6 lipopolysaccharides. Antibiot Chemother (1971). 1991; 44:163-71.
    View in: PubMed
    Score: 0.088
  5. Pharmacodynamic and protective properties of a murine lipopolysaccharide-specific monoclonal antibody in experimental Pseudomonas aeruginosa pneumonia in mice. Microbiol Immunol. 1991; 35(12):1131-41.
    View in: PubMed
    Score: 0.088
  6. Isolation, structure, and immunogenicity of Pseudomonas aeruginosa immunotype 4 high-molecular-weight polysaccharide. Infect Immun. 1989 Feb; 57(2):426-31.
    View in: PubMed
    Score: 0.077
  7. The virulence of Pseudomonas aeruginosa. Rev Infect Dis. 1984 Sep-Oct; 6 Suppl 3:S617-26.
    View in: PubMed
    Score: 0.057
  8. Immunization with Pseudomonas aeruginosa high-molecular-weight polysaccharides prevents death from Pseudomonas burn infections in mice. Infect Immun. 1984 Feb; 43(2):759-60.
    View in: PubMed
    Score: 0.055
  9. Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans. J Infect Dis. 1983 Jun; 147(6):1090-8.
    View in: PubMed
    Score: 0.052
  10. Clinical significance of serum antibody responses to exotoxin A and type-specific lipopolysaccharides in patients with Pseudomonas aeruginosa infections. Am J Med. 1983 Jun; 74(6):980-7.
    View in: PubMed
    Score: 0.052
  11. Toxoid from exotoxin A of Pseudomonas aeruginosa: preparation and characterization. J Infect Dis. 1982 May; 145(5):688-98.
    View in: PubMed
    Score: 0.048
  12. Pseudomonas aeruginosa exotoxin A. N Engl J Med. 1980 Jun 12; 302(24):1360-2.
    View in: PubMed
    Score: 0.043
  13. Toxicity of Pseudomonas aeruginosa exotoxin A for human macrophages. Infect Immun. 1978 Mar; 19(3):1092-6.
    View in: PubMed
    Score: 0.036
  14. Mechanism of action of Pseudomonas aeruginosa exotoxin A in experimental mouse infections: adenosine diphosphate ribosylation of elongation factor 2. Infect Immun. 1978 Jan; 19(1):29-33.
    View in: PubMed
    Score: 0.036
  15. Purification of Pseudomonas aeruginosa exotoxin by affinity chromatography. Infect Immun. 1978 Jan; 19(1):66-70.
    View in: PubMed
    Score: 0.036
  16. Serum antibody to Pseudomonas aeruginosa exotoxin measured by a passive hemagglutination assay. J Clin Microbiol. 1977 Jul; 6(1):58-61.
    View in: PubMed
    Score: 0.035
  17. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection. Invest Ophthalmol Vis Sci. 1997 Jun; 38(7):1418-25.
    View in: PubMed
    Score: 0.034
  18. Exotoxin production by clinical isolates of pseudomonas aeruginosa. Infect Immun. 1977 Mar; 15(3):776-80.
    View in: PubMed
    Score: 0.034
  19. Neutralizing antibody to Pseudomonas aeruginosa exotoxin in human sera: evidence for in vivo toxin production during infection. Infect Immun. 1976 Oct; 14(4):942-7.
    View in: PubMed
    Score: 0.033
  20. Functionally active monoclonal antibody that recognizes an epitope on the O side chain of Pseudomonas aeruginosa immunotype-1 lipopolysaccharide. Infect Immun. 1986 Sep; 53(3):656-62.
    View in: PubMed
    Score: 0.016
  21. Functionally distinct monoclonal antibodies reactive with enzymatically active and binding domains of Pseudomonas aeruginosa toxin A. Infect Immun. 1986 Jun; 52(3):756-62.
    View in: PubMed
    Score: 0.016
  22. Immunochemical characterization of high-molecular-weight polysaccharide from Fisher immunotype 3 Pseudomonas aeruginosa. Infect Immun. 1984 Aug; 45(2):309-13.
    View in: PubMed
    Score: 0.014
  23. Pseudomonas aeruginosa exotoxin A inhibits proliferation of human bone marrow progenitor cells in vitro. Infect Immun. 1982 Oct; 38(1):206-11.
    View in: PubMed
    Score: 0.012
  24. Passive protection by antitoxin in experimental Pseudomonas aeruginosa burn infections. Infect Immun. 1977 Dec; 18(3):596-602.
    View in: PubMed
    Score: 0.009
  25. The outlook for prevention and treatment of infections due to Pseudomonas aeruginosa. Rev Infect Dis. 1984 Sep-Oct; 6 Suppl 3:S769-74.
    View in: PubMed
    Score: 0.004
  26. Circulating immune complexes in cystic fibrosis. Pediatr Res. 1980 Jun; 14(6):830-3.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.